Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07KFB
|
|||
| Former ID |
DIB016639
|
|||
| Drug Name |
Varespladib methyl
|
|||
| Synonyms |
A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 3 | [1] | |
| Company |
Shionogi & Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22N2O5
|
|||
| Canonical SMILES |
CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N
|
|||
| InChI |
1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
|
|||
| InChIKey |
VJYDOJXJUCJUHL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 172733-08-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Secretory phospholipase A2 (sPLA2) | Target Info | Modulator | [2], [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01130246) VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43. | |||
| REF 3 | Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. | |||
| REF 4 | Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs. 2009 Sep;12(9):585-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.